Search company, investor...

Investors Count

2

Deal Terms

1

Funding, Valuation & Revenue

3 Fundings

Singular Genomics's latest funding round was a IPO for $178.5M on May 27, 2021.

Singular Genomics's latest post-money valuation is from May 2021.

Sign up for a free demo to see Singular Genomics's valuations in May 2021 and more.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

5/27/2021

IPO

$178.5M

$99M

0

FY undefined

1

1/1/2019

Seed VC

$99M

0

FY undefined

10

Other Investors

$99M

0

FY undefined

0

Date

5/27/2021

1/1/2019

Round

IPO

Seed VC

Other Investors

Amount

$178.5M

Investors

Valuation

$99M

$99M

$99M

Revenue

0

FY undefined

0

FY undefined

0

FY undefined

Sources

1

10

0

You're one click away from the most comprehensive, unmatched analyst expertise in tech, in-depth private company data and a platform that brings it all together.
Click Now. Join a live demo
Join a demo
CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo

Singular Genomics Deal Terms

1 Deal Term

Singular Genomics's deal structure is available for 1 funding round, including their IPO from May 27, 2021.

Round

IPO

Funding Date

$99M

Pre-Money Valuation

$99M

Post-Money Valuation

$99M

Amount Raised

$99M

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

$99M

Board Voting

$99M

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

IPO

$99M

$99M

$99M

$99M

$99M

$99M

Singular Genomics Investors

2 Investors

Singular Genomics has 2 investors. F-Prime Capital invested in Singular Genomics's Seed VC funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

1/1/2019

1/1/2019

1
Seed VC

Venture Capital

Massachusetts

ARCH Venture Partners

Subscribe to see more

Venture Capital

Illinois

First funding

1/1/2019

Last Funding

1/1/2019

Investor

ARCH Venture Partners

Rounds

1
Seed VC

Subscribe to see more

Board Seats

Type

Venture Capital

Venture Capital

Location

Massachusetts

Illinois

CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo

Compare Singular Genomics to Competitors

A
Algorithmic Biologics

Algorithmic Biologics focuses on molecular diagnostics and discovery through technology in the biotech sector. Their main offerings include a software platform with molecular testing workflows to improve efficiency and accuracy, leveraging AI and molecular computing research. The company primarily serves the healthcare industry, particularly in the areas of genomics research and clinical diagnostics. It was founded in 2021 and is based in Bangaluru, India.

Everist Health Logo
Everist Health

Everist Health (formerly Everist Genomics and Genetics Squared) is a personalized medicine company which develops and commercializes medically unique diagnostics, prognostics and therapeutic selection technologies. Through their tools, the company seeks to help physicians improve medical outcomes and reduce the total cost of care. EGI's products integrate with mobile digital services, smartphones, and tablet computers resulting in advanced medical technology.

Solidus Biosciences Logo
Solidus Biosciences

Solidus Biosciences is a company focused on providing business intelligence in the pharmaceutical and biologic drugs sector. The company's main services include offering insights on life cycle management, brand erosion, generic entry, biosimilars, patents, sales, litigation, and more, all related to pharmaceutical and biologic drugs. The company primarily serves the biopharmaceutical industry. It is based in Troy, New York.

Basepair Logo
Basepair

Basepair is a bioinformatics company operating in the healthcare and technology sectors. The company provides a next-generation data analysis platform for Next-Generation Sequencing (NGS), offering services such as RNA-Seq Analysis, ChIP-Seq Analysis, DNA-Seq Analysis, and ATAC-Seq Analysis. Basepair primarily serves academic researchers, clinical laboratories, library prep kit manufacturers, R&D teams, and sequencing service providers. It was founded in 2015 and is based in New York, New York.

SeekGene Logo
SeekGene

SeekGene specializes in single-cell sequencing and TCR-pMHC pairing technologies in understanding immune responses in the single-cell resolution to help screen, treat and monitor diseases.

Singleron Biotechnologies Logo
Singleron Biotechnologies

Singleron Biotechnologies operates as a biotechnology company. It focuses on applying single-cell analysis technologies. The company offers a comprehensive solution for single-cell multi-omics sequencing, which allows for novel approaches in clinical research and molecular diagnostics. Singleron primarily serves the healthcare industry, particularly in areas of clinical diagnosis, drug development, and health management. It was founded in 2018 and is based in Koln, Germany.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.